This page shows you your search results in order of date.
Order by Relevance | Date
Total 18 results found since Jan 2013.
Exploring the risk factors for ischemic cerebrovascular disease in systemic lupus erythematosus: A single-center case-control study
ConclusionCutaneous vasculitis and antiphospholipid antibodies (aPLs) are associated with an increased risk of ICVD, while HCQ therapy may provide protection against ICVD in SLE. The ICVD in younger lupus patients is associated with complement-mediated inflammation and poorer outcome, and require immunosuppressive therapy, whereas the ICVD in elderly patients are characterized by moderate ICAS and carotid atherosclerotic plaques.
Source: Frontiers in Immunology - September 27, 2022 Category: Allergy & Immunology Source Type: research
Aneurysms in primary antiphospholipid syndrome: a case-based review
This article review ed all published cases on APS and aneurysm and showed that women who presented with abortions and deep venous thromboses with a lupus anticoagulant are those patients more commonly affected by aneurysms in APS.
Source: Clinical Rheumatology - January 3, 2021 Category: Rheumatology Source Type: research
Effects of Antimalarial Drugs on Neuroinflammation-Potential Use for Treatment of COVID-19-Related Neurologic Complications
AbstractThe SARS-CoV-2 virus that is the cause of coronavirus disease 2019 (COVID-19) affects not only peripheral organs such as the lungs and blood vessels, but also the central nervous system (CNS) —as seen by effects on smell, taste, seizures, stroke, neuropathological findings and possibly, loss of control of respiration resulting in silent hypoxemia. COVID-19 induces an inflammatory response and, in severe cases, a cytokine storm that can damage the CNS. Antimalarials have unique properti es that distinguish them from other anti-inflammatory drugs. (A) They are very lipophilic, which enhances their ability to cross ...
Source: Molecular Neurobiology - November 27, 2020 Category: Neurology Source Type: research
Pharmacological and cardiovascular perspectives on the treatment of COVID-19 with chloroquine derivatives.
Abstract The novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19) and an ongoing severe pandemic. Curative drugs specific for COVID-19 are currently lacking. Chloroquine phosphate and its derivative hydroxychloroquine, which have been used in the treatment and prevention of malaria and autoimmune diseases for decades, were found to inhibit SARS-CoV-2 infection with high potency in vitro and have shown clinical and virologic benefits in COVID-19 patients. Therefore, chloroquine phosphate was first used in the treatment of COVID-19 in China. Later, under a lim...
Source: Acta Pharmacologica Sinica - September 22, 2020 Category: Drugs & Pharmacology Authors: Zhang XL, Li ZM, Ye JT, Lu J, Ye LL, Zhang CX, Liu PQ, Duan DD Tags: Acta Pharmacol Sin Source Type: research
We Need a COVID-19 Vaccine. We Also Need Transparency About Its Development
The authorization of an effective vaccine will mark perhaps the biggest turning point in the battle against coronavirus, but only if enough people are willing to get vaccinated. There have been substantial declines in public willingness to get vaccinated against COVID-19, despite immense, unprecedented public investments in vaccine development. In one survey, barely half of Americans said they would get the vaccine as soon as it was available, numbers that will undermine the benefits of even a highly effective vaccine. It is no mystery why trust in a potential vaccine has plummeted. Operation Warp Speed, the Trump Administ...
Source: TIME: Health - September 18, 2020 Category: Consumer Health News Authors: Dr. Ashish K. Jha Tags: Uncategorized COVID-19 Source Type: news
Torsades de Pointes in Coronavirus Disease 2019 Infection
A 73-YEAR-OLD MAN (weight 69 kg, height 175 cm) was transferred to the authors ’ critical care unit with respiratory and acute renal failure secondary to coronavirus disease 2019 (COVID-19) infection. His past medical history included hypertension, diabetes, and previous stroke, from which he had made a full recovery. The patient was treated with mechanical ventilation and p eritoneal dialysis. He was recruited into the hydroxychloroquine arm of the RECOVERY (Randomised Evaluation of COVID-19 Therapy) trial.
Source: Journal of Cardiothoracic and Vascular Anesthesia - July 31, 2020 Category: Anesthesiology Authors: Bagrat Lalabekyan, Gudrun Kunst, Vanessa A. Skelton Tags: Diagnostic Dilemma Source Type: research
Antimalarial and cytotoxic drugs on COVID-19 and the cardiovascular burden: Literature review and lessons to be learned.
DISCUSSION: There is no convincing clinical evidence of chloroquine, hydroxychloroquine with or without azithromycin, and remdesivir use in COVID-19. As evidence of systemic inflammation is rapidly unfolding, there is a dire need to maximize our resources to find the best possible solutions to the current crisis while conclusive evidence from clinical trials emerges. PMID: 32691699 [PubMed - as supplied by publisher]
Source: Vascular - July 20, 2020 Category: Surgery Authors: Sultan S, Acharya Y Tags: Vascular Source Type: research
Behcet's Disease With Cerebral Artery Infarction Caused by Cerebral Arteritis as an Early Symptom Only With Elevated Interleukin-8
Conclusion: This case demonstrates that neurological involvement might be an early symptom of BD. IL-8 could act as a novel target for the treatment of BD theoretically and probably play a key role in disease recovery.
Source: Frontiers in Neurology - October 21, 2019 Category: Neurology Source Type: research
Cardiovascular comorbidities in rheumatoid arthritis.
Abstract Approximately 80% of patients with rheumatoid arthritis (RA) suffer from comorbidities including more than 50% from cardiovascular (CV) diseases. Inflammatory activity is the main factor connecting RA with atherosclerosis, coronary heart disease, stroke, thromboembolic events and heart failure. Altogether these affect RA patients twice as frequently as the general population and CV events are the major cause of death in RA. Besides inflammatory activity, which can be reduced or eliminated by optimal treatment and controlling the RA activity, traditional CV risk factors also contribute to the total CV ris...
Source: Zeitschrift fur Rheumatologie - January 17, 2019 Category: Rheumatology Authors: Krüger K, Nüßlein H Tags: Z Rheumatol Source Type: research
Recurrent cerebellar infarction associated with hereditary heterozygous protein C deficiency in a 35-year-old woman: A case report and genetic study on the pedigree.
In conclusion, the clinical manifestations of hereditary PROC deficiency may vary between individuals. The heterozygous mutation locus c.565C>T on the PROC gene is associated with thrombophilia. Awareness of the association between natural anticoagulants and thrombophilia may promote the prevention and therapy of stroke. PMID: 30210609 [PubMed]
Source: Experimental and Therapeutic Medicine - September 14, 2018 Category: General Medicine Tags: Exp Ther Med Source Type: research
Methotrexate might reduce ischemic stroke in patients with rheumatoid arthritis: a population ‐based retrospective cohort study
ConclusionsAt a dosage of > 0.5 defined daily dose, short‐term methotrexate might decrease ischemic stroke risk in RA patients, while hydroxychloroquine and sulfasalazine were neutral.
Source: APLAR Journal of Rheumatology - January 1, 2018 Category: Rheumatology Authors: Hong ‐Wei Tam, Chyong‐Mei Chen, Pui‐Ying Leong, Chao‐Hsi Chen, Yuan‐Chao Li, Yu‐Hsun Wang, Li‐Chi Lin, Jeng‐Yuan Chiou, James Cheng‐Chung Wei Tags: Original Article Source Type: research
Effect of long-term hydroxychloroquine on vascular events in patients with systemic lupus erythematosus: a database prospective cohort study
ConclusionLong-term HCQ appears to have no vascular protective effect in patients with SLE.
Source: Rheumatology - September 27, 2017 Category: Rheumatology Source Type: research
Cerebral Venous Sinus Thrombosis in A Patient with Sj ögren's Syndrome with Atypical Antibodies: A Case Report.
CONCLUSION: This case reports the relationship between cerebral venous sinus thrombosis and Sjögren's syndrome. It is necessary to screen autoimmune disorders in patients with cerebral venous sinus thrombosis that present with no common risk factors of venous thrombosis in order to prevent inappropriate management, and potentially adverse outcomes. PMID: 27854095 [PubMed - in process]
Source: Acta Neurologica Taiwanica - November 19, 2016 Category: Neurology Tags: Acta Neurol Taiwan Source Type: research
Antiphospholipid Syndrome-Associated Crescendo Stroke Events Treated with Rituximab (P4.351)
Discussion APS is an autoimmune condition associated with persistent antiphospholipid antibodies, characterised by thrombosis and pregnancy morbidity .Regarding APS and stroke the optimal antithrombotic agent, intensity of anticoagulation, and duration of treatment remains controversial. Analysis of the APASS subgroup in the WARS study found aspirin and warfarin to be equally effective agents for secondary stroke prevention . The majority of panel members at the International Congress on Antiphospholipid Antibodies recommended warfarin or combination aspirin and warfarin for patients with definite APS and arterial...
Source: Neurology - April 3, 2016 Category: Neurology Authors: O' Connor, A., Murphy, G., Cronin, S. Tags: Cerebrovascular Case Reports Source Type: research
Prevention of Recurrent Thrombosis in Antiphospholipid Syndrome: Different from the General Population?
Abstract Antiphospholipid syndrome (APS) is characterized by arterial and/or venous thrombosis with or without pregnancy morbidity in the presence of autoantibodies targeting proteins that associate with membrane phospholipids, termed “antiphospholipid antibodies” (aPL). Management of arterial and venous thromboses shares some similarities with management of arterial and venous thromboses in the general population; however, there are key differences. The majority of studies addressing management of thrombotic APS focus on secondary prevention. Vitamin K antagonists (VKA) are typically used for secondary preve...
Source: Current Rheumatology Reports - March 30, 2016 Category: Rheumatology Source Type: research